Biodegradable Nanoparticles (NPs) are under intense investigation due to their potential application in targeted drug delivery. Upon their entry to the biological system, they encounter the immune system, which limits their availability at the intended site. Most importantly, the innate immune system is the one that acts as the first line of defense against foreign materials. It can be activated by collectin proteins which recognize the structural pattern of polysaccharide on the surface of microorganisms. NPs may interact with these proteins in a similar way, and the interaction may lead to beneficial outcomes in vaccine delivery. On the other hand, in targeted drug delivery, it is desirable for the NPs not to be recognized as foreign material as this may lead to their fast elimination from the system through mechanism such as opsonization. We investigated the interaction of PEGylated and un-PEGylated PLGA NPs with Recombinant Human Mannose-Binding Protein (HMBP) in an effort to understand the effect of surface modification on their binding to the protein.
Introduction
Particles with the size ranging from 1 nm to 100 nm are called nanoparticles (NPs). They possess enhanced or altered physical, chemical and biological properties which make them superior in different applications than the corresponding bulk counterparts [1]- [9] . Physical properties of materials at the nano scale are different from their bulk properties; therefore properties of NPs such as reactivity, catalytic activity, strength, etc. could be altered fundamentally. Because of NPs' unique properties, there has been a dramatic increase in emerging new use of NPs for various applications, including drug delivery. Biodegradable polymeric NPs such as poly (D, L-lactide-co-glycolide) (PLGA), polylactic acid (PLA), gelatin and poly-alkyl-cyano-acrylates (PACA) are attracting a great deal of research interest due to their potential to deliver therapeutic molecules such as vaccines, drugs, and genes to target cells [10] - [16] . The use of biodegradable NPs in drug delivery systems arises from their unique and various properties including biocompatibility, versatility, better drug stability, encapsulation and controlled release. Several studies for particle uptake by target cells have demonstrated that properties of NPs such as shape, surface modification, and particle size significantly increase the intracellular uptake rate compared to unmodified NPs [17] [18] [19] [20] . On the other hand, various studies have also shown that NPs interact with the host cell immune systems and lead to either immune stimulation or immune suppression; some NPs may be unrecognized by the immune system and remain in circulation for a long period [21] - [28] . Each of this may have advantages and disadvantages depending on the intended purpose of the NPs delivery system [29] 
Materials and Experimental Methods

Materials
Unmodified poly (D, L-lactide-co-glycolide) (PLGA-COOH) and modified (PLGA-PEG-NH2) NPs were prepared in Dr. Aryal's Lab by nanoprecipitation technique as reported elsewhere [15] [35] [36] . In brief, 1 mg of PLGA-COOH in 100 µL acetonitrile was added dropwise into 1mL Milli-Q water under magnetic stirring. The mixture was stirred continuously overnight to evaporate organic solvent. The PLGA-COOH nanoparticles were further purified using Amicon Ultra-4 centrifugal filter (Millipore, MA) with a molecular weight cutoff of 1000 kDA. Modified PLGA-PEG-NH 2 were prepared by adding 100 μL PLGA (1 mg) into 2 mL 4% ethanol containing 200 μg DSPE-PEG-NH 2 , 260 μg Egg-PC under magnetic stirring condition at 60˚C, followed by addition of 1 mL Milli-Q water and purified as described above (TEM image of representative sample shown in Figure 1 ). Recombinant Human Mannose-Binding Protein C/MBL-2 (HMBP) was purchased from Novoprotein Scientific (Summit, NJ)
with Greater than 95% purity as determined by reducing SDS-PAGE (Amino acid sequence of HMBP is shown on Table 1 ). All chemicals used for this expe- 
Binding of Modified and Unmodified Biodegradable Nanoparticles with HMBP Monitored by Fluorescence Spectroscopy
Since the protein contains tryptophan residues within its structure, the fluorescence emission of tryptophan was used to monitor its binding with the NPs. The maximum absorption wavelength for the HMBP determined to be 280 nm (data not shown) by a hybrid multi-mode microplate reader (Synergy H1, BioTek, Winooski, VT), and this wavelength was used as an excitation wavelength in the binding assay. Various concentrations of the HMBP were prepared, and their spectrum was taken using the micro plate reader at 280 nm excitation wavelength to determine the working concentration range as well as the maximum fluorescence emission wavelength to be used for the binding assay. From the spectra obtained, the right concentration for the binding assay was identified and the maximum emission wavelength was determined to be 330 nm (data not shown). The binding assay was performed by incubating 25 μL of various concentrations (0.004 μM -0.8 μM) of PLGA-COOH or PLGA-PEG-NH 2 with 75 μL of HMBP to get a final concentration of 1 μM HMBP. The sample was incubated for 40 min in phosphate buffered saline (PBS, pH 7.4) at 37˚C on a shaker incubator with a 100 rpm and the emission spectra at 330 nm were taken using the excitation wavelength of 280 nm. PBS and HMBP solutions were used as negative and positive controls, respectively.
Determination of Protein Corona Formation on Unmodified and Modified Biodegradable NPs
The size of PLGA-COOH and PLGA-PEG-NH 2 NPs in the absence and presence HMBP was monitored by DLS (Zetasizer Nano ZS, Malvern Instruments, Worcestershire, UK). PLGA-COOH or PLGA-PEG-NH 2 biodegradable NPs with various concentrations (0.004 μM -0.8 μM) were incubated with 1 μM HMBP in PBS buffer at pH 7.4. The samples were incubated for 40 min at 37˚C in a shaker incubator with 100 rpm, and change in the size of the NPs determined in the absence and presence of HMBP. 
ELISA Binding Assay for the Interaction of Recombinant Human Mannose-Binding Protein with Mannan from Saccharomyces cerevisiae
Result and Discussion
Unmodified poly (D, L-lactide-co-glycolide) (PLGA-COOH) and modified 
Conclusion
Modification of the surface of biodegradable NPs such as PLGA affects their interaction with Collectin proteins (Mannose Binding Proteins). Based on their modification they could be recognized by the host cell innate defense mechanism as a threat to the organism and could be quickly eliminated from the host cell. On the other hand, drug delivery NPs designed with appropriate modifications for a particular target could avoid premature elimination from the system.
Surface modification of NPs is an attractive and promising area to be explored, and has great potential for making efficient drug delivery systems. We have shown here that modified PLGA (PLGA-PEG-NH 2 ) displayed different binding profiles from unmodified PLGA. However, further competition binding study will be needed to determine the specificity of the binding. Moreover, a complete understanding of modified NPs' interaction with a range of proteins in the innate immune system will provide a pool of appropriate modifications for effective drug delivery system. In future work we envision to achieving this by using different modifications and various proteins of the immune system to create a data base. Once these objectives are achieved, immune assay could be used to monitor cellular immune responses for better understanding of its application. 
